Glaxo Granted EU Marketing Authorisation For COPD Treatment Incruse
LONDON (Alliance News) - GlaxoSmithKline PLC said Monday that its compound Incruse had been granted marketing authorisation by the European Commission as a treatment for chronic obstructive pulmonary disease. Glaxo expects the product to launch in Europe by the end of 2014. Incruse is Read More